Dong-Xing Zheng1 
,
Ji-Hai Jin2,
Yu-Juan Liu3
For correspondence:- Dong-Xing Zheng Email: zhengdx5566@163.com
Accepted: 28 February 2018 Published: 31 March 2018
Citation: Zheng D, Jin J, Liu Y. Comparison of capecitabine and tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma in the elderly. Trop J Pharm Res 2018; 17(3):543-547 doi: 10.4314/tjpr.v17i3.22
© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To analyse and compare the clinical effects and safety of capecitabine and tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma.
Methods: Eighty-four metastatic breast cancer elderly patients for whom first or second-line treatment had failed, were selected from among those admitted to the oncology ward of Binjiang People’s Hospital, China between January 2014 and June 2015. They were randomly divided into S-1 group (n = 41) and capecitabine group (n = 41) and received varying doses of those drugs according to body surface area. Clinical effects, progression-free survival, and incidence of adverse reactions were compared for the two groups following treatment.
Results: Disease control rate (CR) in S-1 group was 55.6 %, much higher than 35.1 % observed for capecitabine group (p < 0.05). The disease control rate for the S-1 group was 93.7 %, also much higher than the 70.6 % found in capecitabine group. Survival analysis showed that the median survival times of the two groups did not differ significantly (p > 0.05). Furthermore, some adverse reactions such as myelosuppression and lack of strength, did not differ significantly between the two groups (p > 0.05), whereas others, including leukopenia, nausea and vomiting and hand-foot syndrome were more serious and frequent in capecitabine group than in S-1 group (p < 0.05).
Conclusion: Monotherapy with S-1 is more effective than that with capecitabine. Adverse reactions are minimal for both drugs
Archives
News Updates
Fulltext in PDF